Humalog copay card12/17/2023 It is especially important to perform a safety test when a patient is using a new pen for the first time.ĭo not withdraw Toujeo from the SoloStar and Max SoloStar single-patient-use prefilled pens with a syringe.Ĭlick here for full Prescribing Information.Ĭlick here for information on Sharps Medical Waste Disposal.Ĭlick here to learn more about Sanofi's commitment to fighting counterfeit drugs.Īll registered trademarks cited are property of their respective owners.Įligibility Restrictions and Offer Terms: To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen otherwise they may not get the correct amount of insulin, which may affect their blood glucose levels. Toujeo SoloStar and Toujeo Max SoloStar are single-patient-use prefilled insulin pens. Important Safety Information for Toujeo SoloStar ® and Toujeo Max SoloStar ® The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).Īdverse reactions commonly associated with Toujeo include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema and weight gain. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.Ĭertain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. ![]() These patients should be observed for signs and symptoms of heart failure. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated.įluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of thiazolidinediones (TZDs) with insulin. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Discontinue Toujeo, monitor and treat if indicated.Ī reduction in the Toujeo dose may be required in patients with renal or hepatic impairment.Īs with all insulins, Toujeo use can lead to life-threatening hypokalemia. Severe life-threatening, generalized allergy, including anaphylaxis, can occur. Do not administer Toujeo via an insulin pump or intravenously because severe hypoglycemia can occur. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Patients should be instructed to always verify the insulin label before each injection.ĭo not dilute or mix Toujeo with any other insulin or solution. Medication errors, such as accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. Hypoglycemia is the most common adverse reaction of insulin therapy, including Toujeo, and may be life-threatening. Higher doses were required in titrate-to-target studies to achieve glucose control similar to Lantus. When changing from another basal insulin to Toujeo, patients experienced higher average fasting plasma glucose levels in the first few weeks of therapy until titrated to their individualized fasting plasma glucose targets. Unit for unit, patients started on, or changed to, Toujeo required a higher dose than patients controlled with Lantus. ![]() Advise patients to rotate injection site to unaffected areas and closely monitor for hypoglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis may result in hyperglycemia sudden change in the injection site (to unaffected area) has been reported to result in hypoglycemia. ![]() Changes in insulin regimen may result in hyperglycemia or hypoglycemia. Changes in insulin regimen, strength, manufacturer, type, injection site or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment. Modify insulin regimens only under medical supervision. Monitor blood glucose in all patients treated with insulin. Insulin pens and needles must never be shared between patients. The concentration of insulin glargine in Toujeo is 300 units per mL. Toujeo contains the same active ingredient, insulin glargine, as Lantus ®. Toujeo is contraindicated during episodes of hypoglycemia and in patients hypersensitive to insulin glargine or any of its excipients.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |